Close 10 Sep 1505 scanned A
NIFTY 5023,477.80+0.20%
BANK NIFTY56,471.95+0.31%
INDIA VIX11.80-1.05%
MIDCAP 15022,904.25-0.38%
SMALLCAP 25018,433.40+0.01%
NEXT 5072,530.90-0.44%
BREADTH61%above 200-DMA
ADV / DEC558 / 939
NSE close 10 Sep
The arena Mark Minervini

momentumMark Minervini

Trade Like a Stock Market Wizard

Only own stocks already in a confirmed uptrend, near their highs, outperforming the market.

-1.77%
Booked, per closed position
25 closed · average excess vs the market
20%
Closed positions ahead of the market
median -1.97%
+10.70%
Open book, marked to market
9 names still held
3
Average sessions held
window is 20 sessions

The rule, as implemented here

every condition, in the order it is applied
  1. Price above both the 150-day and the 200-day moving average.
  2. The 150-day average is itself above the 200-day average.
  3. The 200-day average is rising, not merely being crossed.
  4. The 50-day average sits above both longer averages, and price above it.
  5. At least 30% above the 52-week low.
  6. Within 25% of the 52-week high.
  7. One-year return in the top 30% of our universe.
Ranking: Highest relative-strength percentile first. Portfolio is the top 12 names, equal-weighted.
Where our version differs: Relative strength is measured as a percentile of one-year return across our universe, in place of the proprietary IBD RS rating.

Today’s portfolio

as of 10 September 2026

Portfolio record by window

every published day, measured forward and averaged. “Typical day” is the median excess, which ignores one runaway session
WindowPortfolioUniverseExcessTypical dayDays aheadDays scored
1d+0.39%+0.09%+0.30%+0.47%50%14
5d+2.98%+0.60%+2.38%+2.88%100%10
10d+7.70%+1.20%+6.51%+7.42%100%5
20dnot yetnot yetnot yetnot yetnot yet0
3mnot yetnot yetnot yetnot yetnot yet0

Booked positions

closed, with the market over the identical days
StockInOutHeldReturnUniverseExcess
HFCL2026-09-042026-09-104+0.83%+0.16%+0.67%
SAKAR2026-09-022026-09-106+13.34%+1.31%+12.03%
SALSTEEL2026-08-242026-09-1013-0.56%+1.30%-1.86%
PRIZOR2026-09-082026-09-091-2.00%-0.01%-1.99%
AEROFLEX2026-09-072026-09-081+2.75%+0.14%+2.61%
WELCORP2026-09-072026-09-081+0.06%+0.14%-0.08%
VENUSREM2026-09-032026-09-072-1.91%+0.60%-2.51%
MODISONLTD2026-09-022026-09-073-8.65%+1.22%-9.87%
AEROFLEX2026-09-032026-09-041-0.87%+0.52%-1.39%
ATHERENERG2026-08-312026-09-033-4.59%+0.18%-4.77%
HFCL2026-08-212026-09-039-3.34%+0.87%-4.21%
AEROFLEX2026-09-012026-09-021-2.05%-0.08%-1.97%
OBSCP2026-08-212026-09-028+1.54%+0.23%+1.30%
DPEL2026-08-212026-09-017+1.86%+0.30%+1.56%
AEROFLEX2026-08-282026-08-311-3.08%-0.23%-2.85%
BHAGYANGR2026-08-282026-08-311-1.62%-0.23%-1.39%
AIMTRON2026-08-272026-08-281-0.16%+0.41%-0.58%
SKYGOLD2026-08-252026-08-283-3.67%+0.63%-4.30%
AEROFLEX2026-08-262026-08-271-2.66%-0.20%-2.46%
AIMTRON2026-08-242026-08-262-1.94%+0.37%-2.30%
BHAGYANGR2026-08-242026-08-251-1.45%-0.06%-1.39%
RPTECH2026-08-212026-08-252-11.11%+0.08%-11.19%
VENUSREM2026-08-212026-08-241-2.95%+0.12%-3.07%
SANSERA2026-08-212026-08-241-0.84%+0.12%-0.96%
MTARTECH2026-08-212026-08-241-3.09%+0.12%-3.22%

Open book

still held, marked to the last close
StockInOutHeldReturnUniverseExcess
ACCENTMIC2026-09-09held1+1.85%-0.02%+1.87%
BHAGYANGR2026-09-08held2+10.24%-0.01%+10.25%
MAHASTEEL2026-08-31held8-3.02%+0.91%-3.92%
MTARTECH2026-08-25held12+5.43%+1.30%+4.13%
SIGMAADV2026-08-21held14+15.21%+1.50%+13.70%
INDSWFTLAB2026-08-21held14+14.54%+1.50%+13.03%
BLISSGVS2026-08-21held14+20.95%+1.50%+19.45%
STLTECH2026-08-21held14+36.29%+1.50%+34.79%
KPL2026-08-21held14+4.48%+1.50%+2.97%
How these numbers were made. Computed here from NSE and BSE end-of-day bhavcopy, adjusted for splits and bonuses, not supplied by anyone being measured. Portfolios are recorded on the day they are published and scored forward from that date, so no figure on this page could have been chosen after the outcome was known. The code that produced them is stamped in build.json.
This is our implementation, not Mark Minervini’s portfolio. Relative strength is measured as a percentile of one-year return across our universe, in place of the proprietary IBD RS rating. None of the authors named on this site are associated with it, and nothing here is advice or a recommendation to buy or sell anything.